NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 305 filers reported holding NOVOCURE LTD in Q3 2022. The put-call ratio across all filers is 1.44 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $4,559 | +4.1% | 60 | -4.8% | 0.00% | – |
| Q2 2022 | $4,379 | -37.1% | 63 | -25.0% | 0.00% | – |
| Q1 2022 | $6,959 | +15.9% | 84 | +5.0% | 0.00% | – |
| Q4 2021 | $6,006 | -72.8% | 80 | -57.9% | 0.00% | -100.0% |
| Q3 2021 | $22,072 | -45.6% | 190 | +3.8% | 0.00% | -50.0% |
| Q2 2021 | $40,593 | +207.1% | 183 | +83.0% | 0.00% | +100.0% |
| Q1 2021 | $13,218 | -23.6% | 100 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $17,304 | +210.9% | 100 | +100.0% | 0.00% | – |
| Q3 2020 | $5,566 | -92.2% | 50 | -95.9% | 0.00% | -100.0% |
| Q2 2020 | $71,634 | +431.9% | 1,208 | +504.0% | 0.01% | +400.0% |
| Q1 2020 | $13,468 | +59.8% | 200 | +100.0% | 0.00% | 0.0% |
| Q4 2019 | $8,427 | -82.1% | 100 | -84.1% | 0.00% | -75.0% |
| Q3 2019 | $47,111 | – | 630 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Nordwand Advisors, LLC | 1,515,000 | $111,125,249 | 13.86% |
| Invus Financial Advisors, LLC | 350,884 | $25,737,341 | 13.70% |
| HARTLINE INVESTMENT CORP/ | 304,482 | $22,333,755 | 5.08% |
| GREAT POINT PARTNERS LLC | 241,000 | $17,677,350 | 3.46% |
| Tri Locum Partners LP | 72,400 | $5,311,000 | 2.15% |
| Taylor Frigon Capital Management LLC | 42,061 | $3,085,174 | 1.75% |
| HighVista Strategies LLC | 28,007 | $2,054,313 | 1.22% |
| HAP Trading, LLC | 124,500 | $10,294 | 1.05% |
| Private Harbour Investment Management & Counsel, LLC | 12,285 | $901,105 | 0.99% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 32,000 | $2,344,000 | 0.72% |